It is predicted that just under a quarter of a million women in the United States will be diagnosed with breast cancer in 2016. Between 15% and 30% of those women will have tumors found to be positive for the growth-promoting protein HER2.
Although there are several FDA-approved agents available to target HER2 directly, there is still much that is unknown about predicting who will benefit from these drugs, knowing how to effectively combine them with traditional chemotherapy, finding optimal dosing and scheduling, and importantly, combatting the development of resistance in metastatic disease.
The Journal of the Advanced Practitioner in Oncology, or JADPRO, presents HER2-Positive Breast Cancer Updates, a monthly educational newsletter and enduring resource for advanced practitioners. As the editor of the program, I will share articles and news items containing the latest in treatment and management strategies. Next month, we’ll take a look at the most relevant and potentially practice-changing results to come out of the Annual Meeting of the American Society of Clinical Oncology.
Please feel free to share this newsletter with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at email@example.com at any time.
Until next time, take a look at the links I’ve gathered for you here. I hope you find this to be a useful resource in your practice!
Heather Greene, MSN, FNP, AOCNP®
The West Cancer Center